Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-MarketGlobeNewsWire • 01/29/24
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology ConferenceGlobeNewsWire • 01/11/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Checkpoint Therapeutics, Inc. - CKPTPRNewsWire • 01/06/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Checkpoint Therapeutics, Inc. - CKPTPRNewsWire • 12/19/23
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party ManufacturerGlobeNewsWire • 12/18/23
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent IssuanceGlobeNewsWire • 12/05/23
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/13/23
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of CancerGlobeNewsWire • 10/18/23
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross ProceedsGlobeNewsWire • 10/02/23
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare ConferenceGlobeNewsWire • 09/21/23
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/14/23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-MarketGlobeNewsWire • 07/31/23
Checkpoint Therapeutics: Cosibelimab Data Bolsters Case For Dual-Approval In cSCCSeeking Alpha • 07/30/23
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 07/27/23
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval DosingGlobeNewsWire • 06/28/23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 05/23/23
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/15/23